Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APOL1-risk alleles modulate T-cell receptor signaling to promote allograft rejection.

The Journal of clinical investigation·2026
Same author

Efavirenz 400 vs 600 mg combined with lamivudine and tenofovir in treatment-naïve HIV-infected patients in China: A randomized, multi-centered, controlled trial.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Author Correction: A ZFYVE21-Rubicon-RNF34 signaling complex promotes endosome-associated inflammasome activity in endothelial cells.

Nature communications·2026
Same author

Spectroscopic and structural insights into magnetized water: Evidence of hydrogen-bond reorganization.

Talanta·2026
Same author

Endothelial MHC expression is required to initiate T cell-mediated rejection of 3D-printed skin grafts.

JCI insight·2026
Same author

Distinct Blood and Lung Proteins Drive Pulmonary Capillary Leak in Children With Severe Hypoxemic Respiratory Failure.

Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·2026

Related Experiment Video

Updated: May 19, 2026

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

AIP1 in graft arteriosclerosis.

Wang Min1, Jordan S Pober

  • 1Interdepartmental Program in Vascular Biology and Therapeutics and the Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA. wang.min@yale.edu

Trends in Cardiovascular Medicine
|August 21, 2012
PubMed
Summary

AIP1 inhibits graft arteriosclerosis (GA) by reducing smooth muscle-like cell proliferation and migration. This finding offers a potential therapeutic target for preventing cardiac allograft failure.

More Related Videos

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

Related Experiment Videos

Last Updated: May 19, 2026

Mouse Models for Graft Arteriosclerosis
07:37

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

Area of Science:

  • Immunology
  • Cardiovascular Biology
  • Transplantation Science

Background:

  • Graft arteriosclerosis (GA) is a primary cause of late cardiac allograft failure.
  • GA involves intimal hyperplasia driven by infiltrating immune cells and graft-derived smooth muscle-like cells.
  • Interferon-gamma (IFN-γ) is a key mediator of smooth muscle-like cell proliferation in GA.

Purpose of the Study:

  • To investigate the role of AIP1, a vascular inflammation signaling adaptor, in IFN-γ-mediated GA.
  • To elucidate the mechanisms by which AIP1 influences intimal formation in cardiac allografts.

Main Methods:

  • Utilized mouse genetics to establish and study two novel IFN-γ-mediated models of GA.
  • Examined the function of AIP1 in the context of vascular inflammation and smooth muscle-like cell behavior.

Main Results:

  • AIP1 was found to inhibit intimal hyperplasia in the established GA models.
  • AIP1 functions by downregulating IFN-γ-activated signaling pathways responsible for smooth muscle-like cell migration and proliferation.

Conclusions:

  • AIP1 plays a protective role against intimal formation in graft arteriosclerosis.
  • Targeting AIP1 may represent a novel therapeutic strategy to mitigate cardiac allograft vasculopathy and improve long-term transplant survival.